{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:58:13Z","timestamp":1790686693905,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Elevar Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01686-6","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:15:53Z","timestamp":1788009353000},"page":"1565-1574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Rivoceranib 200 mg Once Daily on the Pharmacokinetics of a Cocktail Probe Substrate of Cytochrome P450 Enzymes: A Phase I Trial in Healthy Volunteers"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct03561298","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui Tracey","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1316-3349","authenticated-orcid":false,"given":"Seong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"7","key":"1686_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","volume":"102","author":"S Tian","year":"2011","unstructured":"Tian S, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374\u201380. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01939.x.","journal-title":"Cancer Sci"},{"issue":"26","key":"1686_CR2","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219\u201325. https:\/\/doi.org\/10.1200\/JCO.2013.48.8585.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1686_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448\u201354. https:\/\/doi.org\/10.1200\/JCO.2015.63.5995.","journal-title":"J Clin Oncol"},{"key":"1686_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.749083","volume":"11","author":"Z Tian","year":"2021","unstructured":"Tian Z, Niu X, Yao W. Efficacy and response biomarkers of apatinib in the treatment of malignancies in China: a review. Front Oncol. 2021;11:749083. https:\/\/doi.org\/10.3389\/fonc.2021.749083.","journal-title":"Front Oncol"},{"key":"1686_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-820","volume":"14","author":"X Hu","year":"2014","unstructured":"Hu X, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. https:\/\/doi.org\/10.1186\/1471-2407-14-820.","journal-title":"BMC Cancer"},{"issue":"8","key":"1686_CR6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ijc.28829","volume":"135","author":"X Hu","year":"2014","unstructured":"Hu X, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135(8):1961\u20139. https:\/\/doi.org\/10.1002\/ijc.28829.","journal-title":"Int J Cancer"},{"issue":"7","key":"1686_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","volume":"6","author":"S Qin","year":"2021","unstructured":"Qin S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(7):559\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(21)00109-6.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"1686_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10637-019-00828-x","volume":"38","author":"H Luo","year":"2020","unstructured":"Luo H, et al. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive-stage small cell lung cancer. Invest New Drugs. 2020;38(1):148\u201359. https:\/\/doi.org\/10.1007\/s10637-019-00828-x.","journal-title":"Invest New Drugs"},{"issue":"6","key":"1686_CR9","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1016\/j.cllc.2018.06.002","volume":"19","author":"F Wu","year":"2018","unstructured":"Wu F, et al. A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer. Clin Lung Cancer. 2018;19(6):e831\u201342. https:\/\/doi.org\/10.1016\/j.cllc.2018.06.002.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"1686_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ygyno.2017.12.013","volume":"148","author":"M Miao","year":"2018","unstructured":"Miao M, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2018;148(2):286\u201390. https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.013.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1686_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","volume":"8","author":"Y Lin","year":"2022","unstructured":"Lin Y, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial. JAMA Oncol. 2022;8(2):242\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6268.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1686_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2571.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1686_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000696","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020;8(1):e000696. https:\/\/doi.org\/10.1136\/jitc-2020-000696.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1686_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamaoncol.2022.2253","volume":"8","author":"T Wang","year":"2022","unstructured":"Wang T, et al. Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial. JAMA Oncol. 2022;8(8):1169\u201376. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2253.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1686_CR15","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","volume":"26","author":"S Qin","year":"2025","unstructured":"Qin S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. Lancet Oncol. 2025;26(12):1598\u2013611. https:\/\/doi.org\/10.1016\/S1470-2045(25)00543-1.","journal-title":"Lancet Oncol"},{"key":"1686_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li J, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. https:\/\/doi.org\/10.1186\/1471-2407-10-529.","journal-title":"BMC Cancer"},{"issue":"6","key":"1686_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/dmd.112.050310","volume":"41","author":"J Ding","year":"2013","unstructured":"Ding J, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013;41(6):1195\u2013210. https:\/\/doi.org\/10.1124\/dmd.112.050310.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1686_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jcph.1016","volume":"58","author":"X Liu","year":"2018","unstructured":"Liu X, et al. Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. J Clin Pharmacol. 2018;58(3):347\u201356. https:\/\/doi.org\/10.1002\/jcph.1016.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1686_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0009-9236(03)00229-7","volume":"74","author":"S Chainuvati","year":"2003","unstructured":"Chainuvati S. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the \u201cCooperstown 5+1 cocktail.\u201d Clin Pharmacol Ther. 2003;74(5):437\u201347. https:\/\/doi.org\/10.1016\/S0009-9236(03)00229-7.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1686_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1365-2125.2009.03548.x","volume":"68","author":"S Turpault","year":"2009","unstructured":"Turpault S, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928\u201335. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03548.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1686_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/clpt.2010.158","volume":"88","author":"BC Goh","year":"2010","unstructured":"Goh BC, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652\u20139. https:\/\/doi.org\/10.1038\/clpt.2010.158.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1686_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcph.1496","volume":"60","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, et al. Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: a study with the modified Cooperstown 5+1 cocktail. J Clin Pharmacol. 2020;60(1):86\u201395. https:\/\/doi.org\/10.1002\/jcph.1496.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1686_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bcp.12936","volume":"82","author":"JQ Tran","year":"2016","unstructured":"Tran JQ, et al. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach. Br J Clin Pharmacol. 2016;82(1):160\u20137. https:\/\/doi.org\/10.1111\/bcp.12936.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1686_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/cts.12557","volume":"11","author":"Y Ishii","year":"2018","unstructured":"Ishii Y, et al. Clinical drug-drug interaction potential of BFE1224, prodrug of antifungal ravuconazole, using two types of cocktails in healthy subjects. Clin Transl Sci. 2018;11(5):477\u201386. https:\/\/doi.org\/10.1111\/cts.12557.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1686_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bcp.13424","volume":"84","author":"M Tachibana","year":"2018","unstructured":"Tachibana M, et al. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. Br J Clin Pharmacol. 2018;84(1):112\u201321. https:\/\/doi.org\/10.1111\/bcp.13424.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1686_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cts.12600","volume":"12","author":"JJ Xiao","year":"2019","unstructured":"Xiao JJ, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58\u201365. https:\/\/doi.org\/10.1111\/cts.12600.","journal-title":"Clin Transl Sci"},{"key":"1686_CR27","unstructured":"US FDA. M12 drug interaction studies: guidance for industry. 2024."},{"issue":"6","key":"1686_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","volume":"105","author":"A Tornio","year":"2019","unstructured":"Tornio A, et al. Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 2019;105(6):1345\u201361. https:\/\/doi.org\/10.1002\/cpt.1435.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1686_CR29","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/bcp.14707","volume":"87","author":"YC Ou","year":"2021","unstructured":"Ou YC, et al. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. Br J Clin Pharmacol. 2021;87(7):2926\u201336. https:\/\/doi.org\/10.1111\/bcp.14707.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1686_CR30","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/bcp.15699","volume":"89","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. Br J Clin Pharmacol. 2023;89(7):2236\u201345. https:\/\/doi.org\/10.1111\/bcp.15699.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1686_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cts.12588","volume":"12","author":"K Narushima","year":"2019","unstructured":"Narushima K, et al. Assessment of CYP-mediated drug interactions for evocalcet, a new calcimimetic agent, based on in vitro investigations and a cocktail study in humans. Clin Transl Sci. 2019;12(1):20\u20137. https:\/\/doi.org\/10.1111\/cts.12588.","journal-title":"Clin Transl Sci"},{"issue":"22","key":"1686_CR32","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1158\/1078-0432.CCR-23-1030","volume":"29","author":"GJ Hanna","year":"2023","unstructured":"Hanna GJ, et al. A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2023;29(22):4555\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1030.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01686-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01686-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01686-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:20:07Z","timestamp":1790684407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01686-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01686-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David Nguyen has no conflicts of interest that are directly relevant to the content of this article. Xiaohui (Tracey) Wei, Xianzhang Meng, and Kristin Ryan declare employment with Elevar Therapeutics. Laura Alexander and Seong Jang declare former employment with Elevar Therapeutics.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Alpha Institutional Review Board and conducted in compliance with the study protocol, the International Standard of Good Clinical Practice, the ethical principles of the Declaration of Helsinki, and applicable regulatory requirements. All of the healthy volunteers provided written informed consent prior to enrollment.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study volunteers provided written informed consent prior to participating in this study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study volunteers provided written informed consent for publication of the results of this study.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are not publicly available but could be requested from the corresponding author.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DN, XW, XM, LA, KR, and SJ participated in the interpretation of the study results and in the drafting, critical revision, and approval of the final version of this manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}